Who are Irbesartan/Amlodipine high's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): valsartan/amlodipine, valsartan/amlodpine, Irbesartan/Amlodipine, Fimasartan/Amlodipine, Rosuvastatin, Fimasartan/Amlodipine combination, Irbesartan/Amlodipine low.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/irbesartan-amlodipine-high.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Irbesartan/Amlodipine high — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Irbesartan/Amlodipine high (Irbesartan/Amlodipine high) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Angiotensin II receptor blocker / Calcium channel blocker combination. Area: Cardiovascular.

phase 3 Angiotensin II receptor blocker / Calcium channel blocker combination AT1 receptor / L-type calcium channel Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Irbesartan/Amlodipine high (Irbesartan/Amlodipine high) — Handok Inc.. This combination drug blocks angiotensin II receptors and calcium channels to reduce blood pressure through dual vasodilation and reduced vascular resistance.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Irbesartan/Amlodipine high TARGET	Irbesartan/Amlodipine high	Handok Inc.	phase 3	Angiotensin II receptor blocker / Calcium channel blocker combination	AT1 receptor / L-type calcium channel
valsartan/amlodipine	valsartan/amlodipine	Novartis	marketed	Angiotensin II receptor blocker / Calcium channel blocker combination	AT1 receptor / L-type calcium channel
valsartan/amlodpine	valsartan/amlodpine	University of Pavia	marketed	Angiotensin II receptor blocker / Calcium channel blocker combination	AT1 receptor / L-type calcium channel
Irbesartan/Amlodipine	Irbesartan/Amlodipine	Handok Inc.	phase 3	Angiotensin II receptor blocker / Calcium channel blocker combination	AT1 receptor / L-type calcium channel
Fimasartan/Amlodipine, Rosuvastatin	Fimasartan/Amlodipine, Rosuvastatin	Boryung Pharmaceutical Co., Ltd	phase 3	Angiotensin II receptor antagonist / Calcium channel blocker / HMG-CoA reductase inhibitor (statin)	AT1 receptor / L-type calcium channel / HMG-CoA reductase
Fimasartan/Amlodipine combination	Fimasartan/Amlodipine combination	Boryung Pharmaceutical Co., Ltd	phase 3	Angiotensin II receptor blocker / Calcium channel blocker combination	AT1 receptor / L-type calcium channel
Irbesartan/Amlodipine low	Irbesartan/Amlodipine low	Handok Inc.	phase 3	Angiotensin II receptor blocker / Calcium channel blocker combination	AT1 receptor / L-type calcium channel

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Angiotensin II receptor blocker / Calcium channel blocker combination class)

Handok Inc. · 3 drugs in this class
Institut für Pharmakologie und Präventive Medizin · 2 drugs in this class
Chong Kun Dang Pharmaceutical · 1 drug in this class
Daiichi Sankyo Co., Ltd. · 1 drug in this class
HK inno.N Corporation · 1 drug in this class
Novartis · 1 drug in this class
Boryung Pharmaceutical Co., Ltd · 1 drug in this class
University of Pavia · 1 drug in this class
COLM Study Research Organization · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Irbesartan/Amlodipine high — Competitive Intelligence Brief. https://druglandscape.com/ci/irbesartan-amlodipine-high. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab